PROTHENA CORPORATION PUBLIC LIMITED COMPANY Retained Earnings
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Retained Earnings of -$1.33 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.33B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.31B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.35B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.32B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.33B 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$1.31B 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$1.35B 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$1.32B 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$1.29B 10-Q · filed 2025-08-04 |
| 2025-03-31 | -$1.16B 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$1.10B 10-K · filed 2026-02-27 |
| 2024-09-30 | -$1.04B 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$985.38M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$1.05B 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$980.03M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$912.55M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$934.46M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$879.87M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$833.00M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$839.35M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$793.59M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$752.34M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$716.05M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$682.88M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$792.12M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$819.76M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$783.03M 10-K · filed 2022-02-25 |
| 2020-09-30 | -$752.31M 10-Q · filed 2020-11-04 |
| 2020-06-30 | -$721.74M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$695.45M 10-Q · filed 2020-05-06 |
| 2019-12-31 | -$671.88M 10-K · filed 2021-02-26 |
| 2019-09-30 | -$650.33M 10-Q · filed 2019-11-05 |
| 2019-06-30 | -$630.88M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$615.07M 10-Q · filed 2019-05-07 |
| 2019-01-01 | -$594.21M 10-K · filed 2020-03-03 |
| 2018-12-31 | -$598.00M 10-K · filed 2020-03-03 |
| 2018-09-30 | -$575.53M 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$550.98M 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$491.09M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$442.35M 10-K · filed 2019-03-15 |
| 2017-09-30 | -$394.59M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$342.20M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$324.50M 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$289.21M 10-K · filed 2018-02-26 |
| 2016-09-30 | -$240.31M 10-Q · filed 2016-11-02 |
| 2016-06-30 | -$197.07M 10-Q · filed 2016-08-02 |
| 2016-03-31 | -$156.62M 10-Q · filed 2016-05-04 |
| 2015-12-31 | -$129.10M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$104.95M 10-Q · filed 2015-11-02 |
| 2015-06-30 | -$81.97M 10-Q · filed 2015-08-05 |
| 2015-03-31 | -$63.69M 10-Q · filed 2015-05-06 |
| 2014-12-31 | -$48.49M 10-K · filed 2016-02-25 |
| 2014-09-30 | -$35.38M 10-Q · filed 2014-11-04 |
| 2014-06-30 | -$22.20M 10-Q · filed 2014-08-05 |
| 2014-03-31 | -$23.49M 10-Q · filed 2014-05-05 |
| 2013-12-31 | -$41.34M 10-K · filed 2015-03-13 |
| 2013-09-30 | -$30.29M 10-Q · filed 2013-11-12 |
| 2013-06-30 | -$20.60M 10-Q · filed 2013-08-13 |
| 2013-03-31 | -$9.30M 10-Q · filed 2013-05-15 |
| 2012-12-31 | -$345.00K 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |